CIRM Clinical Dashboard

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell or gene therapies for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

CIRM Clinical Dashboard

Disease Areas Investigator Organization Phasesort descending Trial Status Targeted Enrollment Detail
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
  • Bladder or Urinary Tract Disorder
James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Steven Dubinett University of California, Los Angeles Phase 1 Recruiting 24
William Kennedy Excision BioTherapeutics Phase 1 Recruiting 9
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 42
Everett Meyer Stanford University Phase 1 Recruiting 22
Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
  • Sarcoma
Theodore Nowicki University of California, Los Angeles Phase 1 Recruiting 12
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Saul Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Thomas Kipps University of California, San Diego Phase 1 Completed 26
Krystof Bankiewicz Brain Neurotherapy Bio Phase 1 Recruiting 12
Irving Weissman Stanford University Phase 1 Completed 88
  • Corneal Damage
Sophie Deng University of California, Los Angeles Phase 1 Recruiting 20
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
Dennis Slamon University of California, Los Angeles Phase 1 Completed 48
John Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
  • Spina Bifida
Diana Farmer University of California, Davis Phase 1 Recruiting 55
Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
Leo Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
  • Leukemia, Acute Myeloid (AML)
Joseph Woodard Immune-Onc Therapeutics Phase 1 Recruiting 119
Christine Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Jane Lebkowski Geron Corporation Phase 1 Completed 5
Mark Walters University of California, San Francisco Phase 1 Launching N/A
  • Leukemia, Acute Myeloid (AML)
Mark Chao Forty Seven Inc. Phase 1 Active, not recruiting 258
Gary Steinberg Stanford University Phase 1 Recruiting 30
Kristen Johnson Calibr Phase 1 Completed 60
Crystal Mackall Stanford University Phase 1 Recruiting 54
  • B cell cancers
  • Leukemia
  • Leukemia, Acute Myeloid (AML)
Maria Grazia Roncarolo Stanford University Phase 1 Recruiting 22
  • Multiple Myeloma
Rajesh Belani Poseida Therapeutics, Inc. Phase 1 Closed 105
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
Joseph Wu Stanford University Phase 1 Recruiting 18
  • IPEX Syndrome
Rosa Bacchetta Stanford University Phase 1 Recruiting 36
Joseph Rosenthal City of Hope, Beckman Research Institute Phase 1 Recruiting 6
Pamela Contag BioEclipse Therapeutics INC. Phase 1 Recruiting 24
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
Morton Cowan University of California, San Francisco Phase 1 Recruiting 25
  • Alpha Thalassemia Major
Tippi MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
  • Epilepsy
Cory Nicholas Neurona Therapeutics Phase 1 Recruiting 40
David Miklos Stanford University Phase 1 Recruiting 60
  • Immune Disease
  • Pediatrics
  • X-linked Chronic Granulomatous Disease
Donald Kohn University of California, Los Angeles Phase 1/2 Active, not recruiting 16
  • Muscle Injury
Peter Belafsky University of California, Davis Phase 1/2 Recruiting 62
  • Beta Thalassemia
Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Active, not recruiting 6
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Recruiting 28
  • Immune Disease
  • Leukocyte Adhesion Deficiency
Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Active, not recruiting 9
Judith Shizuru Stanford University Phase 1/2 Recruiting 40
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Mehrdad Abedi University of California, Davis Phase 1/2 Recruiting 18
Stephanie Cherqui University of California, San Diego Phase 1/2 Recruiting 6
Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
Nancy Lane University of California, Davis Phase 1/2 Completed 58
  • Pulmonary Hypertension
  • Vascular Disease
Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Active, not recruiting 26
William van der Touw Celularity Inc Phase 1/2 Active, not recruiting 86
Steven Deeks University of California, San Francisco Phase 1/2 Launching N/A
Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 138
Manasi Jaiman ViaCyte, Inc. Phase 1/2 Active, not recruiting 75
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Francois Binette Lineage Cell Therapeutics Inc. Phase 1/2 Completed 25
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
Donald Kohn University of California, Los Angeles Phase 2 Completed 10
Henry Klassen jCyte, Inc Phase 2 Completed 84
  • COVID-19
Michael Matthay University of California, San Francisco Phase 2 Recruiting 120
Rachel Smith Capricor, Inc Phase 2 Closed 156
William Sietsema Caladrius Biosciences Phase 2 Completed 113
Linda Marban Capricor, Inc Phase 2 Completed 25
David Williams Boston Children's Hospital Phase 2 Active, not recruiting 10
  • Leukemia, Acute Myeloid (AML)
Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Henry Klassen jCyte, Inc Phase 2 Completed 84
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 414
Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Jeffrey Lawson Humacyte, Inc. Phase 3 Recruiting 240
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 263
Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Active, not recruiting 30
Icon for XLSX export